About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00750425

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.

Lead sponsor: AstraZeneca•5 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Written informed consent
•Histological or cytological confirmation of advanced solid tumour (with the exception of prostate cancer), which is refractory to standard therapies or for which no standard therapy exists.
•Estimated life expectancy of at least 8 weeks
•WHO performance status (PS) 0-2.

Exclusion Criteria

•Unstable brain/meningeal metastases
•Biochemistry/haematology results outside of required ranges
•History of significant GI impairment
•Inadequate bone marrow reserve

Related studies

RECRUITINGPhase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937 · Small Cell Lung Cancer, Melanoma, and more

RECRUITINGPhase 1

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

NCT07387068 · Advanced Solid Tumors

RECRUITINGPhase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

NCT07360314 · Advanced Solid Tumors

RECRUITINGPhase 1

A Study of HDM2024 in Participants With Advanced Solid Tumors

NCT07539285 · Advanced Solid Tumors

RECRUITINGPhase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

NCT07403721 · Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 10, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment46

Start dateAug 2008

Last updatedMar 10, 2011

Condition

Advanced Solid Tumors

Locations shown

Research Site

Hamilton

Research Site

Toronto

Research Site

Vancouver

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2011Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions